Because rapamycin modulates gene expression postranscriptionally [31,47,48], we are also seeking to determine whether incorporation of functional proteomics complements gene expression profiling in identification of patients with breast cancer who have activation of mTOR signaling and monitoring response of breast cancer to therapy. The gene discussed is MTOR; the disease is breast carcinoma.